Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)
China · Delayed Price · Currency is CNY 22.74
+1.11 (5.13%)
At close: Aug 4, 2026
SHA:688217 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,194 | 1,454 | 1,018 | 1,999 | 1,965 | 4,042 | |
Market Cap Growth | -28.71% | 42.90% | -49.08% | 1.72% | -51.39% | - |
Enterprise Value | 970 | 1,243 | 835 | 1,790 | 1,692 | 3,916 |
Last Close Price | 21.63 | 26.35 | 18.33 | 35.57 | 34.98 | 71.96 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 252.00 | 48.54 | 85.39 |
Forward PE | - | 105.40 | 76.83 | 41.61 | 37.81 | - |
PS Ratio | 7.33 | 8.20 | 4.20 | 7.74 | 4.63 | 13.89 |
PB Ratio | 1.42 | 1.72 | 1.11 | 2.07 | 2.02 | 4.51 |
P/TBV Ratio | 1.47 | 1.79 | 1.19 | 2.30 | 2.27 | 5.08 |
P/FCF Ratio | 105.90 | 77.41 | 49.48 | - | - | - |
P/OCF Ratio | 32.50 | 31.93 | 16.97 | 44.32 | 26.89 | 51.84 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.96 | 7.01 | 3.45 | 6.93 | 3.99 | 13.46 |
EV/EBITDA Ratio | - | - | 36.24 | 61.41 | 16.32 | 65.23 |
EV/EBIT Ratio | - | - | - | - | 23.24 | 144.85 |
EV/FCF Ratio | 86.04 | 66.17 | 40.60 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.02 | 0.03 | 0.01 | 0.01 |
Debt / EBITDA Ratio | - | - | 0.85 | 0.85 | 0.13 | 0.15 |
Debt / FCF Ratio | 0.22 | 0.15 | 1.09 | - | - | - |
Net Debt / Equity Ratio | -0.27 | -0.26 | -0.23 | -0.21 | -0.29 | -0.35 |
Net Debt / EBITDA Ratio | 14.43 | 58.38 | -9.13 | -7.03 | -2.71 | -5.25 |
Net Debt / FCF Ratio | -19.82 | -11.84 | -10.22 | 3.20 | 8.39 | 17.89 |
Asset Turnover | 0.18 | 0.19 | 0.24 | 0.24 | 0.42 | 0.35 |
Inventory Turnover | 1.15 | 1.26 | 1.21 | 1.23 | 3.65 | 2.45 |
Quick Ratio | 16.67 | 12.29 | 10.46 | 10.17 | 6.17 | 14.85 |
Current Ratio | 18.75 | 13.88 | 12.14 | 11.97 | 6.93 | 16.64 |
Return on Equity (ROE) | -7.85% | -6.84% | -2.74% | -0.50% | 7.06% | 5.14% |
Return on Assets (ROA) | -3.29% | -2.59% | -1.18% | -0.59% | 4.48% | 2.04% |
Return on Invested Capital (ROIC) | -7.85% | -5.82% | -2.60% | -1.39% | 10.56% | 4.64% |
Return on Capital Employed (ROCE) | -5.70% | -4.50% | -2.00% | -1.00% | 7.30% | 3.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -4.92% | -3.46% | -1.55% | 0.40% | 2.06% | 1.17% |
FCF Yield | 0.94% | 1.29% | 2.02% | -3.20% | -1.70% | -0.44% |
Dividend Yield | 1.57% | - | - | 0.51% | - | - |
Payout Ratio | - | - | - | 131.08% | 0.03% | 0.04% |
Buyback Yield / Dilution | 3.04% | 1.67% | 0.61% | -2.17% | -11.28% | -19.69% |
Total Shareholder Return | 4.68% | 1.67% | 0.61% | -1.67% | -11.28% | -19.69% |